YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD-L1/VEGFA Axis

Scientists discovered that trimethylated histone H3 lysine 4 and H3 lysine 27 acetylation modification in the promoter region of YTH N6-methyladenosine RNA binding protein 2 (YTHDF2) enhanced its expression in HCC, and upregulated YTHDF2 in HCC predicted a worse prognosis.